SSY vs. SEEL, THAR, TCON, PTPI, PRTG, LFLY, GBNHF, ARTL, VERO, and LIPO
Should you be buying SunLink Health Systems stock or one of its competitors? The main competitors of SunLink Health Systems include Seelos Therapeutics (SEEL), Tharimmune (THAR), TRACON Pharmaceuticals (TCON), Petros Pharmaceuticals (PTPI), Portage Biotech (PRTG), Leafly (LFLY), Greenbrook TMS (GBNHF), Artelo Biosciences (ARTL), Venus Concept (VERO), and Lipella Pharmaceuticals (LIPO). These companies are all part of the "medical" sector.
Seelos Therapeutics (NASDAQ:SEEL) and SunLink Health Systems (NYSE:SSY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation.
Seelos Therapeutics has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Comparatively, SunLink Health Systems has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.
23.4% of Seelos Therapeutics shares are held by institutional investors. Comparatively, 23.7% of SunLink Health Systems shares are held by institutional investors. 5.4% of Seelos Therapeutics shares are held by company insiders. Comparatively, 26.5% of SunLink Health Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Seelos Therapeutics and Seelos Therapeutics both had 6 articles in the media. SunLink Health Systems' average media sentiment score of 0.10 beat Seelos Therapeutics' score of -0.38 indicating that Seelos Therapeutics is being referred to more favorably in the media.
SunLink Health Systems has a net margin of -20.39% compared to SunLink Health Systems' net margin of -1,373.61%. SunLink Health Systems' return on equity of 0.00% beat Seelos Therapeutics' return on equity.
SunLink Health Systems has higher revenue and earnings than Seelos Therapeutics.
Seelos Therapeutics received 71 more outperform votes than SunLink Health Systems when rated by MarketBeat users. Likewise, 66.36% of users gave Seelos Therapeutics an outperform vote while only 0.00% of users gave SunLink Health Systems an outperform vote.
Seelos Therapeutics currently has a consensus price target of $360.00, suggesting a potential upside of 18,846.37%. Given SunLink Health Systems' higher possible upside, research analysts clearly believe Seelos Therapeutics is more favorable than SunLink Health Systems.
Summary
Seelos Therapeutics beats SunLink Health Systems on 8 of the 14 factors compared between the two stocks.
Get SunLink Health Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for SSY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SunLink Health Systems Competitors List
Related Companies and Tools
